TCDA Tricida Inc.

34.04
-0.12  -0%
Previous Close 34.16
Open 34.17
Price To Book 4.85
Market Cap 1,681,247,991
Shares 49,390,364
Volume 46,236
Short Ratio
Av. Daily Volume 189,554

NewsSee all news

  1. Tricida Launches Metabolic Acidosis Insights, an Online Educational Resource for the Healthcare Community

    Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company, announced today the launch of an educational website for healthcare providers. The website, https://metabolicacidosisinsights.com, is an online resource providing

  2. Tricida Announces Submission of New Drug Application for Veverimer for the Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease

    NDA Submitted under the FDA's Accelerated Approval Program Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing announced September 4, 2019.
TRC 101
Chronic kidney disease

Latest News

  1. Tricida Launches Metabolic Acidosis Insights, an Online Educational Resource for the Healthcare Community

    Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company, announced today the launch of an educational website for healthcare providers. The website, https://metabolicacidosisinsights.com, is an online resource providing

  2. Tricida Announces Submission of New Drug Application for Veverimer for the Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease

    NDA Submitted under the FDA's Accelerated Approval Program Tricida, Inc. (NASDAQ:TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a